Please check your internet connection and try again.
# Oxymetazoline Nasal Spray
## Overview
Oxymetazoline is a topical alpha-adrenergic agonist that causes vasoconstriction of nasal mucosa, reducing swelling and congestion.
## Primary Indications
Temporary relief of nasal congestion associated with the common cold, allergic rhinitis, or sinusitis.
## Adult Dosing
**Sinex (0.05% solution):**
Instill 2 to 3 sprays in each nostril every 10 to 12 hours as needed.
Do not exceed 2 doses in a 24-hour period.
Limit use to a maximum of 3 days.
## Pediatric Dosing
**Children 6 to 11 years:**
Instill 2 to 3 sprays in each nostril every 10 to 12 hours as needed.
Do not exceed 2 doses in a 24-hour period.
Limit use to a maximum of 3 days.
**Children under 6 years:**
Not recommended. Consult a pediatrician.
## Dose Adjustments
No specific dose adjustments are generally required for hepatic or renal impairment.
## Contraindications
Hypersensitivity to oxymetazoline or any component of the formulation.
Patients with narrow-angle glaucoma.
## Adverse Effects
Common: Nasal discomfort, burning, stinging, sneezing, increased nasal discharge.
Less Common: Rebound congestion (rhinitis medicamentosa) with prolonged use, dizziness, nervousness, insomnia, palpitations, headache.
## Key Drug Interactions
* **MAO inhibitors and tricyclic antidepressants:** May potentiate the hypertensive effects of oxymetazoline. Avoid concurrent use or use with extreme caution.
## Monitoring
Monitor for signs of rebound congestion (rhinitis medicamentosa) with prolonged or excessive use. Assess for cardiovascular effects (e.g., increased blood pressure, palpitations) if systemic absorption is suspected.
## Clinical Pearls
* Limit use to 3 consecutive days to prevent rebound congestion.
* If congestion persists beyond 3 days, discontinue use and consult a healthcare provider.
* Shake well before use.
* Avoid contact with eyes.
---
*This information is intended for clinical decision-making and does not replace the need to consult the most current prescribing information and relevant literature.*